We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
When Roche delayed its planned $4.8 billion purchase of gene therapy developer Spark Therapeutics for the fifth time earlier this week, citing the Federal Trade Commission's (FTC's) review of the deal, one burning question emerged among pharma watchers: W